Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Delivery Deal Valuations

Executive Summary

In doing deals, large pharmaceutical companies have historically valued the underlying molecule higher than drug delivery mechanisms. But data on deal valuations show that the average valuation of drug delivery deals has jumped considerably over the last three years, with biotech-type deal terms such as large upfront, equity, and milestone payments.
Advertisement

Related Content

Drug Delivery Companies Hop On the Transdermal Express

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV000680

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel